Aricept filed for Lewy body dementia in Japan
This article was originally published in Scrip
Executive Summary
Eisai is seeking the Japanese approval of its one-time Alzheimer's disease blockbuster Aricept (donepezil) for the additional indication of dementia with Lewy bodies (DLB).